Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Partner FOCUSed on Growth

Marketwired November 16, 2015

Knight Supports Operation Antibe

Marketwired November 16, 2015

Knight Reports Third Quarter Financial 2015 Results

Marketwired November 11, 2015

The Knight Medison Relationship Already Paying Dividends

Marketwired November 2, 2015

Knight Profounda U.S. Partner for Impavido

Marketwired September 28, 2015

Knight Takes its Dose of Medison

Marketwired September 9, 2015

GUD Medison Taken at Knight

Marketwired August 31, 2015

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

GlobeNewswire August 26, 2015

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

Marketwired August 26, 2015

NEMO Ascends to New High Water Mark for Knight

Marketwired August 24, 2015

Knight Reports Second Quarter 2015 Results

Marketwired August 12, 2015

Knight and LFB S.A. Announce Filing of New Drug Submission for ATryn(R)

Marketwired August 6, 2015

Ember Therapeutics Raises up to $6M and Establishes Commercial Partnership with Knight Therapeutics

PR Newswire August 6, 2015

Knight Sparks Ember Partnership

Marketwired August 5, 2015

Knight Therapeutics Announces an Exclusive Distribution Agreement for AzaSite(R) in Canada

Marketwired July 24, 2015

Knight Therapeutics Announces an Exclusive Distribution Agreement for AzaSite(R) in Canada

Marketwired July 24, 2015

Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada

Marketwired July 21, 2015

Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada

Marketwired July 21, 2015

Alimera Sciences Signs Knight Therapeutics As Exclusive ILUVIEN® Distributor For Canada

PR Newswire July 21, 2015

Knight Lends a Hand to a New Debt Fund

Marketwired July 9, 2015